ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance
暂无分享,去创建一个
Jinhui Wang | Yate-Ching Yuan | Xiwei Wu | M. Roth | Zheng Liu | R. Bhatia | Zhiqiang Wang | WenYong Chen | Hongfeng Yuan | S. Chu | Mendel M. Roth
[1] Correction: ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance , 2015, PLoS genetics.
[2] M. Roth,et al. Sorting out functions of sirtuins in cancer , 2014, Oncogene.
[3] L. Su,et al. The emerging and diverse roles of sirtuins in cancer: a clinical perspective , 2013, OncoTargets and therapy.
[4] Martin C. Müller,et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. , 2013, Blood.
[5] B. Morris. Seven sirtuins for seven deadly diseases of aging. , 2013, Free radical biology & medicine.
[6] Zhiqiang Wang,et al. Emerging Roles of SIRT1 in Cancer Drug Resistance. , 2013, Genes & cancer.
[7] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[8] Johan Auwerx,et al. Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.
[9] R. Bhatia,et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. , 2012, Blood.
[10] T. Holyoake,et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. , 2012, Cancer cell.
[11] J. Stark,et al. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells , 2012, Oncogene.
[12] M. Roth,et al. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. , 2012, Carcinogenesis.
[13] Zhiqiang Wang,et al. De Novo Acquisition of BCR-ABL Mutations for CML Acquired Resistance , 2011 .
[14] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[15] D. Tenen,et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. , 2010, Blood.
[16] J. Yee,et al. BCR-ABL Gene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia* , 2009, The Journal of Biological Chemistry.
[17] T. Clackson,et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.
[18] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[19] B. Brors,et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence , 2009, Leukemia.
[20] S. Deaglio,et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. , 2008, Physiological reviews.
[21] A. Kauffmann,et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients , 2008, Oncogene.
[22] T. Holyoake,et al. Transcriptional Analysis of Quiescent and Proliferating CD34+ Human Hemopoietic Cells from Normal and Chronic Myeloid Leukemia Sources , 2007, Stem cells.
[23] Junia V. Melo,et al. Chronic myeloid leukaemia as a model of disease evolution in human cancer , 2007, Nature Reviews Cancer.
[24] Fei Huang,et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.
[25] F. Lee,et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice , 2006, Proceedings of the National Academy of Sciences.
[26] T. White,et al. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. , 2006, Biochemical and biophysical research communications.
[27] T. White,et al. Regulation of intracellular levels of NAD: a novel role for CD38. , 2006, Biochemical and biophysical research communications.
[28] C. Goolsby,et al. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. , 2006, Cancer research.
[29] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[30] K. Bhalla,et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.
[31] Thomas J. Lamkin,et al. Retinoic acid‐induced CD38 expression in HL‐60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels , 2006, Journal of cellular biochemistry.
[32] Hongyue Dai,et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Mesirov,et al. From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .
[34] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[35] C. Sawyers,et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. , 2005, Blood.
[36] J. Bennett,et al. Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993) , 2005, Leukemia & lymphoma.
[37] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[38] Il-Jin Kim,et al. Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays , 2004, Clinical Cancer Research.
[39] B. Druker,et al. Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib , 2003, Pharmacological Reviews.
[40] M. Egyed,et al. Effect of Retinoic Acid Treatment on Cytogenetic Remission of Chronic Myeloid Leukaemia , 2003, Acta Haematologica.
[41] E. Fibach,et al. Retinoic Acid Induction of CD38 Antigen Expression on Normal and Leukemic Human Myeloid Cells: Relationship with Cell Differentiation , 2003, Leukemia & lymphoma.
[42] S. Collins. The role of retinoids and retinoic acid receptors in normal hematopoiesis , 2002, Leukemia.
[43] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[44] D. Housman,et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[45] L. Degos,et al. All trans retinoic acid in acute promyelocytic leukemia , 2001, Oncogene.
[46] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[47] D. Cockayne,et al. Signals That Initiate Somatic Hypermutation of B Cells In Vitro1 , 2001, The Journal of Immunology.
[48] U. Thorsteinsdóttir,et al. NUP98–HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice , 2001, The EMBO journal.
[49] F. Malavasi,et al. Human CD38 and related molecules , 2000 .
[50] I. Bernstein,et al. All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells. , 2000, Blood.
[51] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[52] Zhen-yi Wang,et al. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. , 1997, Pharmacology & therapeutics.
[53] Adamson,et al. All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia. , 1996, The oncologist.
[54] M. Andreeff,et al. Retinoic Acid-induced Expression of CD38 Antigen in Myeloid Cells Is Mediated through Retinoic Acid Receptor-α , 1994 .
[55] E. Dmitrovsky,et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.
[56] P. Lansdorp,et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. , 1991, Blood.
[57] F. Malavasi,et al. CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. , 1990, Journal of immunology.
[58] I. Olsson,et al. Myeloid differentiation in liquid cultures of cells from patients with chronic myeloid leukemia: effects of retinoic acid and indomethacin. , 1984, Experimental hematology.
[59] Peter Lloyd,et al. Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.
[60] M. Baccarani,et al. Clinical Observations, Interventions, and Therapeutic Trials , 2000 .
[61] E. Estey,et al. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia , 1997, Leukemia.
[62] M. Andreeff,et al. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. , 1994, Cancer research.
[63] K. Yamada,et al. [Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all-trans-retinoic acid]. , 1994, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[64] I. Miyoshi,et al. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. , 1983, International journal of cell cloning.